Marisa Zammit asks Mike about his background, how Mike came to join Imagion and how Mike thinks Imagion’s technology could transform the imaging industry.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal